Salarius grants $225K transaction bonus to Acting CEO Rosenblum tied to Decoy merger

Decoy Therapeutics Inc.

Board approved $225,000 cash bonus for Acting CEO/CFO Mark J. Rosenblum.
Bonus payable upon closing of the previously announced merger with Decoy Therapeutics.
Payment subject to Rosenblum's continued employment through the closing date.
Rosenblum holds dual roles as Acting CEO and Executive VP/CFO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.